Piper Jaffray Maintains a 'Neutral' on BioMarin (BMRN); Increasing PT Based On MPS IV Patient Pool For GALNS
Tweet Send to a Friend
Piper Jaffray maintains a 'Neutral' rating on BioMarin Pharmaceutical (Nasdaq: BMRN), price target increased from $23 to $25 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
